• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

How CGM tech has advanced in the 21st century

March 11, 2021 By Brian Buntz

Dexcom Seven CGM
Dexcom’s Seven CGM stretched monitoring to up to seven days. [Image courtesy of Dexcom]

Packaging with insulin pumps — and extending monitoring time

2006: Medtronic debuts first integrated insulin pump and CGM system

Medtronic received FDA approval for its MiniMed Paradigm REAL-Time system, which it described as a milestone toward the development of an artificial pancreas. The following year, the company expanded the indication for its CGMs to include patients aged 7–17.

2007: Dexcom introduces the Seven CGM

The device was the first approved for up to seven days of use. A model with updated software known as the Seven Plus (shown here) introduced blood sugar trending arrows. The trend arrows can help people with diabetes anticipate in advance when blood sugars are starting to trend high or low.

2007: Medtronic launches the Guardian REAL-Time system with MiniLink transmitter

The standalone personal CGM features a smaller transmitter than preceding models. The transmitter is waterproof to a depth of 8 feet for up to 30 minutes when connected to the glucose sensor.

Next>>

Pages: Page 1 Page 2 Page 3 Page 4 Page 5 Page 6

Filed Under: Diabetes, Diagnostics, Drug-Device Combinations, Featured Tagged With: abbott, CGM, Dexcom, Medtronic, Senseonics

IN CASE YOU MISSED IT

  • Omnipod 5 rollout for type 2 rolls on as Insulet pursues next-gen automation
  • LifePlus reports clinical validation of non-invasive glucose, blood pressure monitor
  • Abbott Diabetes head talks Medtronic partnership, exciting times ahead
  • PharmaSens, SiBionics innovatively combine tech in all-in-one insulin patch pump
  • Study backs Biolinq intradermal sensor in muscle loss prevention during GLP-1 therapy

About Brian Buntz

The pharma and biotech editor of WTWH Media, Brian is a veteran journalist with more than 15 years of experience covering an array of life science topics, including clinical trials, drug discovery and development and medical devices. Before coming to WTWH, he served as content director focused on connected devices at Informa. In addition, Brian covered the medical device sector for 10 years at UBM. At Qmed, he overhauled the brand’s news coverage and helped to grow the site’s traffic volume dramatically. He had previously held managing editor roles on two of the company’s medical device technology publications. Connect with him on LinkedIn or email at bbuntz@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS